Scaling up its succesful station approachRolling out tried-and-tested concept. Fastned is a clear market leader in highway fast charging in the Netherlands. In the past years it has optimized its concept to provide market-leading reliability and a high service level to customers at competitive costs. It is now rolling out this concept to other European countries, aiming to grow from 346 stations at YE2024 to 1,000 stations by 2030.Significant operating leverage. The stations have been operating ...
Yesterday, Fastned announced it has raised more than EUR34.7m from its second bond issue to retail investors this year, with EUR28.8m contributed in new investments and EUR5.9m rolled from earlier tranches. This brings the total amount of retail bonds raised in 2025 to more than EUR71m (vs EUR82m i
GENFIT: June 17, 2025 Combined Shareholders Meeting Results All resolutions recommended by the Board of Directors approved (quorum: 27.21%). Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 17, 2025. The quorum on first convening amounted to 27.21% and shareholders approved all of the resolutions, with...
GENFIT : Résultats de l’Assemblée Générale Mixte du 17 juin 2025 L’ensemble des projets de résolutions recommandés par le Conseil d’Administration a été approuvé (quorum : 27,21%). Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 17 juin 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui les résultats de son Assemblée Générale Mixte convoquée le 17 juin 2025. Le quorum réuni sur première convocation s’est é...
Ageas: Reinsurance partnership with TRIGLAV, taking QS on Italian motor direct insurance Belgian Telecoms: Digi introduces a new mobile subscription at €3. Kinepolis: Box office in US/Canada up 76% YoY while France visitors were down 25%. NN Group & ASR: Dutch coalition collapse not affecting Dutch Pension Reform. SBM Offshore: Farewell Aseng after 13.5 years of service. Events Calendar
We refresh our Benelux Tech coverage following the 1Q25 reporting season. In this note we downgrade Just Eat Takeaway from Buy to HOLD as we believe the takeover offer is fair. Most companies reported largely in line results and, across the board we make relatively modest changes to our estimates. Our highest conviction longs in the Benelux Tech universe are ASM International, Barco, BE Semiconductor Industries and RELX. Our biggest increase in target price is for Prosus which saw strong perfor...
GENFIT Reports First Quarter 2025 Financial Information Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of March 31, 2025 and revenues for the first three months of 2025.1 Cash position As of March 31, 2025, the Company’s cash and cash equivalents amounted to €129.5 million compared with €74.0 million as of March 31, 2024, and €81.8 million a...
GENFIT : Information financière du premier trimestre 2025 Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 22 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui sa position de trésorerie au 31 mars 2025 et son chiffre d’affaires pour les trois premiers mois de 2025.1 Situation de Trésorerie Au 31 mars 2025, la trésorerie et les équivalents de trésorerie de la Société s’élevaie...
GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen’s Iqirvo® in Italy Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 20, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that Ipsen’s Iqirvo®1 has been granted pricing and reimbursement in Italy for Primary Biliary Cholangitis (PBC). This major step unlocks a new milestone payment of €26.5 million under our Licensing...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.